Condition
Location

11 Epidermolysis Bullosa Trials

Power is an online platform that helps thousands of Epidermolysis Bullosa patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Image of trial facility.

Diacerein Ointment for Epidermolysis Bullosa

Cincinnati, Ohio
The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:6+
Sex:All
80 Participants Needed
Image of trial facility.

Dupilumab for Itchy Skin Diseases

Chicago, Illinois
Severe itch is a common symptom of many genetic skin disorders and leads to a negative impact on patient quality of life. The investigators hypothesize that: a) intervention with dupilumab will improve itch in patients with pruritic genetic inflammatory skin disorders, even those not recognized to be Th2-driven; and b) the administration of dupilumab will be well-tolerated, regardless of underlying genetic skin disorder. The total clinical study duration will be 26 months (104 Weeks). The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:6+
Sex:All
30 Participants Needed
Image of trial facility.

Skin Substitute for Epidermolysis Bullosa

Toronto, Ontario
Single patient study. Patient diagnosed with dystrophic epidermolysis bullosa presenting chronic open wounds that are not responding to dressings, topical preparations (antimicrobials, antibiotics) and systemic agents (anti-inflammatory antibacterials). The Self-Assembled Skin Substitutes will be used to cover wounds.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:All
Sex:All
1 Participants Needed
Image of trial facility.

D-Fi for Epidermolysis Bullosa

Philadelphia, Pennsylvania
The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2+
Sex:All
32 Participants Needed
Image of trial facility.

AGLE 102 for Epidermolysis Bullosa

Philadelphia, Pennsylvania
INVESTIGATIONAL PRODUCT: AGLE-102 is an allogeneic derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). INDICATION AND RATIONALE: The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with Epidermolysis Bullosa (EB). STUDY DESIGN: This is a phase 1/2A, non randomized, multi-center, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with EB.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:6+
Sex:All
10 Participants Needed
Image of trial facility.

Rigosertib for Skin Cancer in Dystrophic Epidermolysis Bullosa

Philadelphia, Pennsylvania
This trial studies how rigosertib sodium, a drug taken orally or through IV, can help treat patients with a rare skin condition and advanced skin cancer who haven't responded to other treatments. The drug targets and kills cancer cells while leaving healthy cells alone. Rigosertib has shown potential as a therapeutic option for nonresectable cholangiocarcinoma, demonstrating antitumoral and radiosensitizing effects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 79
Sex:All
6 Participants Needed
Image of trial facility.

FCX-007 for Epidermolysis Bullosa

Rochester, Minnesota
This trial tests if FCX-007 can improve wound healing in people with RDEB, a condition causing persistent wounds. FCX-007 is injected into the skin to help it heal by providing missing elements. The study observes how treated wounds heal compared to other wounds in the same patients. FCX-007 is a gene therapy designed to deliver COL7A1 to the skin, aiming to restore collagen VII expression and improve wound healing in RDEB patients.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2+
Sex:All
6 Participants Needed
Image of trial facility.

EB-101 for Epidermolysis Bullosa

Worcester, Massachusetts
To evaluate and further characterize the safety of EB-101 (LZRSE-Col7A1 gene-corrected keratinocyte sheets with type VII collagen \[C7\] expression) for the treatment of large, chronic RDEB wounds in new and previously EB-101 treated patients 12 months and older.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
12 Participants Needed
Image of trial facility.

Stem Cell Therapy for Epidermolysis Bullosa

Minneapolis, Minnesota
This trial is testing a special cell therapy given through an IV to people with a severe genetic skin condition called RDEB. The therapy aims to help heal and grow new, healthy skin. Researchers are evaluating its safety and effectiveness. Previous tests have shown increased collagen expression and faster wound healing in patients with RDEB.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6+
Sex:All
74 Participants Needed
Image of trial facility.

ALLO-ASC-SHEET for Epidermolysis Bullosa

Miami, Florida
After confirming eligibility, a single subject with four selected target lesions will receive both ALLO-ASC-SHEET and Vehicle control, three target lesions for ALLO-ASC-SHEET and the other target for Vehicle control, and which lesion to apply which IP treatment will be determined randomly at the time of enrollment using pre-designed block randomization scheme.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:4 - 60
Sex:All
6 Participants Needed
Image of trial facility.

IV IgG for Dystrophic Epidermolysis Bullosa

Redwood City, California
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2
Age:6+
Sex:All
8 Participants Needed
Page 1 of 1+

Frequently Asked Questions

How much do Epidermolysis Bullosa clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Epidermolysis Bullosa clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Epidermolysis Bullosa trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Epidermolysis Bullosa is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Epidermolysis Bullosa medical study ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Epidermolysis Bullosa clinical trials ?

Most recently, we added IV IgG for Dystrophic Epidermolysis Bullosa, D-Fi for Epidermolysis Bullosa and AGLE 102 for Epidermolysis Bullosa to the Power online platform.

Other People Viewed

NEW Diabetes and Pain Medication Study

SAPIEN 3 Valve for Pulmonary Valve Dysfunction

Temperature-Regulating Therapy for Insomnia in Tourette Syndrome

Behavior Parent Education for ADHD in Pre-Kindergarteners

Theta Burst Stimulation for Tourette Syndrome

Cevostamab for Multiple Myeloma

Catheter-Directed Therapy for Post-Thrombotic Syndrome

Cariprazine for Cocaine and Opioid Use Disorder

Cladribine + Rituximab for Hairy Cell Leukemia

Engaging Visual Field Test for Pediatric Eye Examinations

Mitoquinone for Long-COVID

Venetoclax + Ixazomib + Dexamethasone for AL Amyloidosis

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top